HR Execs on the Move

Apollo Endosurgery

www.apolloendo.com

 
Apollo Endosurgery, Inc. is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal conditions. Apollo`s device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo`s products are offered in over 70 countries today and include the OverStitch™ Endoscopic Suturing System, the X-Tack™ Endoscopic HeliX Tacking System, and the ORBERA® Intragastric Balloon.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.apolloendo.com
  • 1120 South Capital of Texas Highway Building 1, Suite 300
    Austin, TX USA 78746
  • Phone: 512.279.5100

Executives

Name Title Contact Details
Steve Bosrock
Vice President of Marketing Profile
Kirk Ellis
Vice President of United States Sales Profile

Similar Companies

Owlet Baby Care

The world`s first infant health tracker, designed to notify you if your baby`s heart rate or oxygen levels fall out of range. Rest assured with Owlet.

Rejuve

Rejuve is a Saratoga, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Instromedix

Instromedix is a Rosemont, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Samco Scientific Corporation

Samco Scientific Corporation is a San Fernando, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seno Medical Instruments

Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to the development and commercialization of a new modality in cancer diagnosis: opto-acoustic imaging. Seno`s Imagio breast imaging system fuses opto-acoustic technology with ultrasound to generate functional and anatomical images of the breast. The opto-acoustic images provide a unique blood map in and around suspicious breast masses while the ultrasound provides a traditional anatomic image. Through the appearance or absence of the two hallmark indicators of cancer – angiogenesis and deoxygenation – Seno believes that the Imagio OA breast imaging system will be a more effective tool to help radiologists confirm or rule out malignancy than current diagnostic imaging modalities – without exposing patients to potentially harmful ionizing radiation (x-rays) or contrast agents.